Facebook
Twitter
LinkedIn
ForwardMiami Cancer Institute – Lung Cancer Conference
The current state of knowledge regarding multi-modality treatment for lung cancer is continually changing and it is important for surgeons, medical oncologists, radiation oncologists and pulmonologist to stay up-to-date on the latest recommendations for the management of the disease. Dr. Mark Dylewski and the distinguished faculty from Miami Cancer Institute and Lynn Cancer Institute will discuss new advances in the management of lung cancer.
Target Audience
Internists, Hospitalists, General Practitioners, Pulmonologists, General Surgeons, Thoracic Surgeons, Obstetricians and Gynecologists, Oncologists, Radiation Oncologists, Nurses, Dietitians, Occupational Therapists, Pharmacists and techs, Respiratory Therapists, Patient Navigators and all other interested healthcare professionals.
Learning Objectives
- Assess the clinical efficacy of postoperative noninvasive positive pressure ventilation after pulmonary lobectomy.
- Develop selective strategies for determining the appropriate extent of resection for individual patients to reduce organ loss.
- Assess the outcomes of patients experiencing complications after robotic pulmonary resection.
- Identify treatment-related factors associated with an increased risk of major complications.
- Identify the benefits of robotic intervention versus thoracotomy or conventional VATS techniques.
- Describe morbidity and mortality rate of complete resection associated with robotic surgery in the treatment of lung cancer.
- Identify the principles of stereotactic body radiotherapy for early-stage non-small cell lung cancer.
- Analyze and assess outcomes for nonoperative management of locally advanced non-small cell lung cancer.
- Accurately assess and execute a thorough workup of a solitary lung nodule.
- Differentiate and evaluate treatment approaches of a lung nodule versus sampled nodule and when to proceed with surgical resection.
- Evaluate bronchoscopic techniques, radial endobronchial ultrasound, navigation bronchoscopy, electromagnetic navigation and robotic platforms.
- Describe results of recent clinical trials that combine targeted therapies with chemotherapy.
- Implement strategies that optimize therapeutic decisions for patients based on individual molecular, genomic and clinical features.
- Analyze current strategies and standard of care for proper pretreatment molecular and PDL-1 testing.
- Execute appropriate treatment with immunotherapy and chemotherapy for patients with advanced non-small cell lung cancer.
- Integrate gene mapping into professional practice updates when treating lung cancer.
- Identify the most effective treatment plan as a result of gene mapping.
- Identify new treatments for resectable lung cancer.
Federico Albrecht, M.D.
Thoracic Oncology
Miami Cancer Institute
Miami, Florida
Federico Albrecht, M.D., faculty for this educational event, is on the speakers’ bureau for Lily Pharmaceutical, Guardant Health Lab and Boehringer Ingelheim. He is also an advisor with GI Therapeutic and Sanofi. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.
All of the relevant financial relationships listed for this individual have been mitigated.
John F. DeRosimo, M.D.
John F. DeRosimo, M.D., faculty for this educational event, has individual stocks/stock options in Intuitive Surgical, Novo- Nordis, Ampio Pharmaceuticlas, Cytodyne Inc. and Heat Biologics Inc. and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.
Mark Dylewski, M.D.
Mark Dylewski, M.D., faculty for this educational event, is on the speakers’ bureau for Intuitive Surgical, and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.
Paul Kaywin, M.D.
Thoracic Medical Oncologist
Miami Cancer Institute
Miami, Florida
Paul Kaywin, M.D., faculty for this educational activity, has no relevant financial relationships with ineligible companies* to disclose, and has indicated that the presentation or discussion will not include off-label or unapproved product usage.
Rupesh Kotecha, M.D.
Director of CNS Metastasis Program
Chief of Radiosurgery
Department of Radiation Oncology
Miami Cancer Institute
Miami, Florida
Rupesh Kotecha, M.D., faculty for this educational event, has received honorariums from Elekta AB, Accuracy Inc., ViewRay, and Elsevier. He has also received research support from Medtronic, B.Earth Diagnostics, Novocure, Exelixis, GT Medical, Astrazeneca and ViewRay. He is on the speakers’ bureau for Novocure and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.
Matthen Mathew, M.D.
Hematologic Oncology
Boca Regional Medical Center
Boca Raton, Florida
Matthen Mathew, M.D., faculty of this educational activity, has no relevant financial relationships with ineligible companies* to disclose, and has indicated that the presentation or discussion will not include off-label or unapproved product usage.
John R. Roberts, M.D.
John R. Roberts, M.D., faculty for this educational event, is a consultant with Scott Flora Consulting and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.
Andres F. Sosa, M.D.
Pulmonary and Critical Care Medicine
Miami Pulmonary Specialists
Miami, Florida
Andres F. Sosa, M.D., faculty for this educational event, is on the speakers’ bureau for GSK and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.
Raul R. Valor, M.D.
Clinical Assistant Professor
Herbert Weirtheim College of Medicine
Florida International University
Chief, Department of Medicine
Baptist Hospital of Miami
Miami, Florida
Raul R. Valor, M.D., faculty for this educational event, is on the speakers’ bureau for GSK, Boehringer and Astrazeneca and is a consultant with Olympus. He has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose with ineligible companies.*
*Ineligible companies - Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been approved for 2.5 credit hours, CE Broker Course #20-858403, by the Florida Boards of Medicine, Osteopathic Medicine and by the Florida Council of Physician Assistants.
This activity has also been approved for 2.5 credit hours for Nurse Practitioners, Nurses, Dietitians, Occupational Therapists, Pharmacists and techs and Respiratory Therapists. Baptist Health South Florida CE Broker Provider #50-182.
Available Credit
- 2.50 AMA PRA Category 1 Credit™
- 2.50 General certificate of attendance
- 2.50 Florida Board of Dietitians
- 2.50 Nurse Practitioners
- 2.50 Florida Board of Nursing
- 2.50 Florida Board of Occupational Therapy
- 2.50 Florida Board of Pharmacy
- 2.50 Florida Board of Respiratory Therapy
Required Hardware/Software
 | PC/Mac UsersThis site is supported on the most recent stable releases of the following browsers:
| ||||||
 | Mobile UsersThis site is supported on the following mobile devices:
| ||||||
 | Technical SupportIf you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours. |
